or Try an Advanced Search...

    Technical Analysis for CPRX - Catalyst Pharmaceutical Partners, Inc.

    Grade Last Price % Change Price Change
    C 20.60 -5.03% -1.09
    CPRX closed down 5.03 percent on Friday, November 15, 2024, on 1.74 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical CPRX trend table...
    Date Alert Name Type % Chg
    Fell Below 50 DMA Bearish 0.00%
    New Downtrend Bearish 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Fell Below 20 DMA Bearish -5.03%
    MACD Bearish Signal Line Cross Bearish -5.03%
    Down 3 Days in a Row Weakness -5.03%
    Down 4 Days in a Row Weakness -5.03%
    Upper Bollinger Band Walk Strength -9.65%
    Older End-of-Day Signals for CPRX ...

       Recent Intraday Alerts

    Alert Time
    Lower Bollinger Band Support 2 days ago
    Fell Below Lower Bollinger Band 2 days ago
    Down 5% 2 days ago
    60 Minute Opening Range Breakdown 2 days ago
    1.5x Volume Pace 3 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    CPRX Chart by TradingView
    Basic chart:

    Profile

    Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company's principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Pharmaceutical Health Sciences Medication Virotherapy Disorders Epilepsy Prescription Drugs Pharmaceutical Sciences Myasthenia Stage Specialty Pharmaceutical Pharmaceutical Partners Treatment Of Epilepsy Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Tourette Syndrome Treatment Of Tourette Syndrome Urological Diseases

    Is CPRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
    Nov 13 Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
    Nov 13 Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point
    Nov 11 Vericel Stock Sees RS Rating Shoot Higher
    Nov 10 Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
    Nov 8 With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case
    Nov 7 Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2024 Earnings Call Transcript
    Nov 7 Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?
    Nov 6 Catalyst (CPRX) Reports Q3 Earnings: What Key Metrics Have to Say
    Nov 6 Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates
    See more CPRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 24.27
    52 Week Low 13.0
    Average Volume 981,623
    200-Day Moving Average 17.42
    50-Day Moving Average 20.99
    20-Day Moving Average 22.04
    10-Day Moving Average 22.52
    Average True Range 0.80
    RSI (14) 39.76
    ADX 29.43
    +DI 21.24
    -DI 30.49
    Chandelier Exit (Long, 3 ATRs) 21.86
    Chandelier Exit (Short, 3 ATRs) 22.85
    Upper Bollinger Bands 23.73
    Lower Bollinger Band 20.34
    Percent B (%b) 0.08
    BandWidth 15.38
    MACD Line 0.38
    MACD Signal Line 0.56
    MACD Histogram -0.178
    Fundamentals Value
    Market Cap 2.45 Billion
    Num Shares 119 Million
    EPS 0.55
    Price-to-Earnings (P/E) Ratio 37.45
    Price-to-Sales 4.66
    Price-to-Book 4.66
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.39
    Resistance 3 (R3) 22.53 22.08 22.09
    Resistance 2 (R2) 22.08 21.63 22.01 21.99
    Resistance 1 (R1) 21.34 21.34 21.12 21.20 21.89
    Pivot Point 20.89 20.89 20.78 20.82 20.89
    Support 1 (S1) 20.15 20.44 19.93 20.01 19.31
    Support 2 (S2) 19.70 20.15 19.63 19.21
    Support 3 (S3) 18.96 19.70 19.11
    Support 4 (S4) 18.82